Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach.

OBJECTIVE: The purpose of this study is to compare the outcome of patients with proximal gastric cancer (PGC) treated by a transabdominal-only resection to that of patients with distal gastric cancer (DGC). SUMMARY BACKGROUND DATA: It has been suggested that PGC is inherently more aggressive than DGC. The worse survival of PGC compared with that of DGC may be in part, because of the difficulty distinguishing PGC from distal esophageal adenocarcinoma. By defining a subset of PGC resected using an transabdominal-only approach, one may discriminate true PGC from distal esophageal adenocarcinoma. This subset of patients is a more appropriate comparison group when analyzing outcome relative to patients with DGC. METHODS: A review of the prospective database for gastric adenocarcinoma at Memorial Sloan-Kettering Cancer Center between July 1985 and August 1995 identified 98 patients with PGC resection via a transabdominal-only approach. Of these, 65 underwent proximal gastrectomy and 33 underwent total gastrectomy. For DGC, 258 required a distal gastrectomy and 71 required total gastrectomy. RESULTS: The overall 5-year survival of patients with PGC was 42% (median survival, 47 months), whereas the 5-year survival for patients with DGC was 61% (median survival, 106 months, p = 0.03). Within each stage, there were no significant survival differences, but in all stages, survival was better for patients with DGC. More important, the site of the primary tumor appears to affect survival, with a worse outcome as the tumor moves proximally. CONCLUSIONS: Despite excluding distal esophageal cancers, survival for patients with PGC remains worse than for those with DGC. Late stage of presentation could not explain this difference. It appears that PGCs are inherently more aggressive than are DGCs. In addition, site of the primary tumor appears to affect outcome, with a trend toward a worse outcome as the tumor moves proximally.     

Stomach adenocarcinoma: what form of gastrectomy?]

Three hundred and sixty consecutive cases of gastric adenocarcinoma were studied retrospectively between 1976 and 1987. Surgery was curative in 195 patients: 91 had a subtotal gastrectomy 83 a total gastrectomy and 21 a proximal gastrectomy. Subtotal and total gastrectomy were compared within this group in terms of postoperative morbidity and mortality, abdominal comfort and 5-year actuarial survival: Postoperative mortality was greater after total gastrectomy (9.6 vs 2.2%, p = 0.04), as were anastomotic leaks (19 vs 2%, p = 0.0009). Mean weight loss was greater after total gastrectomy (p = 0.005). Comparison of patients with similar tumor staging and localization did not show any significant difference in 5-year actuarial survival. If subtotal gastrectomy is certainly justified for distal gastric cancer, it should be considered for some proximal localization.     

原发性胃淋巴瘤的诊断与治疗

目的 探讨原发性胃淋巴瘤的临床特点和治疗方法.方法 回顾性分析23例经病理证实为原发性胃淋巴瘤患者的临床资料.23例均行手术治疗,其中胃大部切除16例(D1 9例,D2 7例),全胃切除3例,姑息性切除术2例,剖腹探查术2例.术后21例患者接受辅助化疗.结果 本组总体5年生存率为80%.低度恶性14例,其巾病史5年以上有10例,生存期超过5年9例;高度恶性9例,病史5年以上有7例(失访2例),生存期超过5年2例.Ⅰ期13例,病史5年以上有10例,生存期超过5年9例;Ⅱ期7例,病史5年以上有5例(失访2例),生存期超过5年2例;Ⅲ～Ⅳ期3例,5年生存0例.根治性手术19例中病史5年以上有14例(失访1例),生存期超过5年12例;非根治性手术4例(失访2例),5年生存0例.低度恶性、早期并获得根治性切除的原发性胃淋巴瘤预后较好.结论 原发性胃淋巴瘤的术前诊断和分期主要依靠胃镜和CT检查.手术和术后辅助治疗是治疗早期原发性胃淋巴瘤的重要手段,非手术疗法是治疗晚期原发性胃淋巴瘤的主要方法.     

Improving outcomes after gastroesophageal cancer resection: can Japanese results be reproduced in Western centers?

HYPOTHESIS Extended lymphadenectomy in gastroesphageal cancer leads to improved long-term survival without compromising postoperative outcomes in Western patients to attain the standard achieved in Japanese centers. DESIGN Cohort study comparing postoperative outcomes and long-term survival with data from the National Cancer Center (NCC) of Tokyo, Japan. Outcomes were also compared with data from the UK National Oesophago-Gastric Cancer Audit (NOGCA) and a representative cohort from southeast England. Prospectively collected data were independently audited. SETTING University medical center. PATIENTS From 2003 to 2010, 100 patients underwent gastrectomy and 109 underwent esophagectomy. MAIN OUTCOME MEASURES Postoperative mortality and morbidity and long-term overall survival. Lymph node count was used as a measure for the extent of lymphadenectomy. RESULTS One death occurred after esophagectomy and none after gastrectomy. Anastomotic leak rate was approximately 2% in both cohorts. Kaplan-Meier estimates of 5-year overall survival after gastrectomy and esophagectomy were 58.4% and 47.8%, respectively. Postoperative mortality and technical complications for gastric and esophageal cancer resections were similar to NCC rates (P?=?.20). Stage for stage 5-year survival rates in patients with esophageal cancer and stages II and III gastric cancer were similar to outcomes in the NCC. The 5-year survival for patients with gastric cancer was worse for those with stage I (P?<?.001) and better for those with stage IV (P?<?.001) disease compared with NCC rates. Postoperative outcomes and long-term survival were significantly better than those reported by the NOGCA and the data from the southeast of England (P?<?.05). CONCLUSIONS This study demonstrates that postoperative outcomes and long-term survival after gastroesophageal cancer resection can be improved in Western patients to the highest standard achieved in Japan.     

胃体癌切除范围对预后影响的临床研究

目的：探讨胃体癌切除范围对预后的影响。方法：回顾性分析2003年4月―2008年4月157例行胃体癌根治性手术患者的临床资料和随访资料,其中行全胃切除术的患者104例（全胃组）,行远端胃次全切除术53例（远端胃组）,对比两组的5年生存率,分析胃体癌预后的独立影响因素。结果：全组患者5年生存率为37.6%,其中全胃组、远端胃组5年生存率分别为24.0%、64.2%,全胃组明显低于远端胃组（χ2=10.635,P=0.001）;为消除两组术前基线资料的差异,将TNM分期分层对比的结果显示,低TNM分期患者中,远端胃组生存率明显高于全胃组（P<0.05）,而高TNM分期患者中,两组生存率差异无统计学意义（P>0.05）。COX回归模型分析结果显示,TNM分期（HR=1.270,95% CI=1.093~2.344）、肿瘤分化程度（HR=1.764,95% CI=1.372~2.746）是胃体癌预后的独立影响因素（均P<0.05）, 而切除范围（HR=0.547,95% CI=0.320~1.076）不是胃体癌预后的独立影响因素（P>0.05）。结论：手术切除范围并非胃体癌预后的独立影响因素,在保证根治性的前提下远端胃次全切除术是更为适宜的术式。

     

Stomach cancer: a study of 117 consecutive resected cases and results of R2-R3 gastrectomy

In a consecutive series of 175 patients with gastric carcinoma, 66.8% underwent gastric resection: 74 total gastrectomies with R3 lymphadenectomy and 43 distal subtotal gastrectomies with R2 lymphadenectomy were performed. 73% (86 cases) of resective procedures proved to be "absolute curative" according to Japanese criteria (JRSGC). Nodal involvement was present in 62 out of 117 resected patients (52.9%): 29.9% N1, 9.4% N2, 13.6% N3; a significant relationship (p = 0.012) between depth of invasion of the gastric wall and lymph node metastases was revealed. The hospital mortality after R2-R3 gastrectomy was 4.2%, major surgical complications occurred in 6.8% of cases. The actuarial 5-year survival after curative resection was 59%. The results suggest that extended lymphadenectomy (R2-R3 gastrectomy) is justified in the surgical treatment of gastric cancer; this procedure can be safely performed and permits "absolute curative" resections in a remarkable percentage of cases.     

Surgery: Independent Prognostic Factor in Curable and Far Advanced Gastric Cancer

The hospital records of 639 patients affected by primary gastric cancer who were consecutively admitted to our unit during the period 1981–1995 were reviewed. Overall 220 underwent total gastrectomy (38 palliative), 12 had resection of the gastric stump, 195 had distal subtotal gastrectomy (55 palliative), 78 had bypass procedures, 72 had explorative laparotomy, and 62 had no operation. Univariate and multivariate analyses were used to evaluate 5-year survival with respect to the main clinical, pathologic, and treatment variables after both curative and palliative treatments. Overall the 5-year survival after curative treatment (320 patients—operative mortality excluded) was 55.5%: 91.1% for stage IA, 71.5% IB, 62.4% II, 37.5% IIIA, 31.5% IIIB. Among patients who underwent palliative treatment 5-year survival was 13.1% after gastric resection (total or distal subtotal), 4.9% after the bypass procedures, 0 after explorative laparotomy, and 0 after no operation. Univariate and multivariate survival analyses showed that variables independently associated with poor survival were advanced stage, upper location and D1 lymphadenectomy after curative treatment, tumor spread to distant sites, and nonresectional surgery after palliative treatment. Multivariate analysis showed that even though survival with gastric cancer depends on predetermined factors, the type of surgery can have a significant effect on prognosis after both curative and palliative treatment.     

胃癌D2根治术联合脾切除与否对疗效影响的比较研究

目的比较胃癌D2根治术中联合脾切除与否对胃上部、上中部及全胃癌手术疗效的差异。方法1989年1月至1994年12月问,对112例肿瘤位于胃上部、上中部或全胃的患者施行了D2根治术．其中61例接受保脾改良淋巴结清除术（保脾组）,51例接受D2根治术联合脾切除（切脾组）。回顾性分析两组患者在临床病理特征、5年生存率、术后并发症发生率和术后住院天数等方面的差异。结果两组胃癌患者在性别、年龄、肿瘤大小、肿瘤T分期和N分期及TNM分期间差异均无统计学意义（均P〉0．05）。保脾组和切脾组胃癌患者的术后5年总体生存率分别为41．0％和39．2％（P〉0．05）。保脾组Ⅰ、Ⅱ、Ⅲ、Ⅳ期胃癌患者的5年生存率分别为100．0％、66．7％、27．8％和17-4％．切脾组分别为100．0％、70．0％、26．7％和5．6％,两组各分期患者术后5年生存率差异均无统计学意义（P〉0．05）：保脾组和切脾组胃癌患者的术后并发症发生率分别为11．5％和27．5％,两组间差异有统计学意义（P〈0．05）;切脾组胃癌患者的术后平均住院天数（27．3d）长于保脾组（20．3d）（P=0．057）。结论对于胃上部、上中部或全胃癌,保脾改良淋巴结清除的D2全胃根治术不仅能取得与联合脾切除的耽全胃根治术相当的疗效,而且可以减少术后并发症的发生率。     

局部进展期胃癌术后进行奥沙利铂联合替吉奥辅助化疗的安全性和有效性

目的:探究奥沙利铂联合替吉奥（SOX）方案作为局部进展期胃癌D 2根治术后辅助化疗方案的安全性和有效性。 方法:采用描述性病例系列研究方法。病例纳入标准：（1）经胃镜活检或手术标本病理证实为胃腺癌;（2）接受D 2根治手术,且术后接受SOX方案辅助化疗。排除标准：（1）术后病理分期为T...     

Results of the surgical treatment of primary gastric lymphoma

The aim of the study was to verify the long term results obtained in primary gastric lymphoma with a strategy consisting in surgery as first-line treatment. Over the period from January 1988 to December 1999, 44 patients with histologically proven primary gastric lymphoma underwent surgical treatment in the First Department of General Surgery of the University of Verona. Tumours were staged according to the Ann Arbor classification and divided, according to the Kiel classification, into high- and low-grade lymphoma. Patients received adjuvant chemotherapy depending on the grade of malignancy and/or completeness of resection. Of the 44 patients, 40 (90.9%) underwent curative resections, i.e. with complete macroscopic and microscopic tumour removal (R0), consisting in total gastrectomy in 34 cases and subtotal gastrectomy in 6. Twenty-five of 40 patients had stage IE and 15 stage IIE tumours. Adjuvant chemotherapy was given to 33 patients (30 high-grade lymphomas and 3 low-grade lymphomas with N2 metastases). The overall cumulative 10-year survival rate in patients who underwent R0 resection was 79% without any significant differences in 10-year survival between patients with high- and low-grade malignancy (both 79%; P = 0.582) or between patients with or without lymph node metastases (91% and 70%, respectively; P = 0.426). In conclusion, the present investigation suggests that surgery yields prolonged complete remission in a high percentage of patients affected by gastric lymphoma irrespective of histopathologic grade of the disease and nodal involvement.     

Cancer of the hypopharynx and cervical esophagus

Between 1975 and 1988 we observed 169 patients with carcinoma of the cervical esophagus, 85 with a carcinoma involving the hypopharynx and the cervical esophagus, and 27 patients with a carcinoma of the cervical esophageal region arising after laryngectomy for laryngeal cancer. The mean age was 57.5 years (range 41-73). 167 patients underwent surgical exploration (operability rate 59.5%) and in 152 cases the tumor was resected (resectability rate 91.1%). The resection was complete in 129 patients (84.5%) and palliative in 23 (14.5%). In 33 cases a segmental laryngo-pharyngo-cervical esophagectomy with free intestinal loop transplantation was performed with an operative mortality of 6.1%. 101 patients underwent total laryngo-pharyngo esophagectomy and the gastrointestinal tract was reconstructed by means of pharyngo-gastrostomy and pharyngo-colostomy in 85 and 16 cases, with an operative mortality of 12.9% and 18.3%, respectively. Total esophagectomy without laryngectomy was performed in 18 patients with a carcinoma of the distal cervical esophagus refusing laryngectomy with a hospital mortality of 5.5%. The overall 5-year actuarial survival, excluding the operative mortality, was 15.8%. After complete resection, better results were recorded with patients operated for carcinoma of the hypopharynx than with patients with carcinoma of the cervical esophagus: the 2-year and 5-year actuarial survival was 59% vs 26% and 43% vs 17%, respectively. No patient undergoing palliative resection was alive at the 3-year interval.(ABSTRACT TRUNCATED AT 250 WORDS)     

Pancreas-preserving total gastrectomy for gastric cancer

BACKGROUND: Pancreas-preserving total gastrectomy for gastric cancer has been proposed to remove lymph nodes along the upper border of the pancreas without performing a distal pancreatic resection. However, the original technique includes the ligation of the splenic artery at its origin and thus carries the risk of pancreatic necrosis. HYPOTHESIS: A technique of pancreas-preserving total gastrectomy that includes ligation of the splenic artery approximately 5 cm distally from the root may reduce the risk of postoperative pancreatic necrosis. DESIGN: Case series. SETTING: Both primary and referral hospital care. PATIENTS: Hospital records of 228 consecutive patients who, according to a personal technique, underwent D3 pancreas-preserving total gastrectomy for gastric cancer from 1981 to 1997 were reviewed. MAIN OUTCOME MEASURES: Surgical complications, postoperative deaths, and survival. RESULTS: Hospital morbidity and mortality were 33.3% and 3.9%, respectively. No patients experienced pancreatic necrosis. The 5-year survival rate after curative resection was 53.6%: 96.9% for stage IA, 76.3% for stage IB, 63.0% for stage II, 35.6% for stage IIIA, 27.0% for stage IIIB, and 20.3% for stage IV (N3-positive patients) disease. CONCLUSION: Results of the present study show the efficacy of this method of radical resection for gastric cancer as demonstrated by the low incidence of postoperative complications and high survival rates.     

胃切除方式对胃中部癌患者预后的影响

目的探讨胃切除方式对胃中部癌患者预后的影响。方法回顾性分析1998年1月至2005年12月间福建医科大学附属协和医院收治的222例胃中部癌患者的临床资料,其中行开腹远端胃大部切除术66例（DG组）,行开腹全胃切除术患者156例（TG组）,比较两组患者术后5年的生存率。结果DG组和TG组术后5年生存率分别为63．9％和49．8％,差异具有统计学意义（P〈0．05）。但相比之下,TG组患者肿瘤更大、分期更晚、肿瘤位于小弯侧者居多（均P〈0．01）。按TNM分期进行分层预后分析显示,相同病期的两组患者术后5年生存率的差异均无统计学意义（均P〉0．05）。无论是以4cm、5cm还是6cm作为近切缘截点,不同近切缘距离患者5年生存率的差异均无统计学意义（均P〉0．05）。多因素预后分析显示,浸润深度、淋巴结转移和TNM分期是独立预后影响因素（均P〈0．05）;而胃切除方式并不是独立预后因素（P〉0．05）。结论胃中部癌患者如果能够达到根治手术的要求,其预后不受胃切除方式的影响,行远端胃大部切除术是可行的。     

Stomach cancer: have changes in surgical strategy influenced the results? 20-year retrospective study

STUDY AIM: The aim of this retrospective study was to compare a group of patients who underwent resection for gastric adenocarcinoma (cancer of cardia excluded) and to assess the influence of radical lymphadenectomy on postoperative mortality and morbidity and 5-year survival rate. PATIENTS AND METHOD: One hundred and six patients were operated on from 1975 to 1985 and 99 from 1986 to 1995 for gastric adenocarcinoma located in the distal portion of the stomach in 56% and 61% respectively and, undifferenciated in 56%. Gastric resection was a subtotal gastrectomy for cancers of the lower third and total gastrectomy for cancers of the middle and superior thirds. In the first group (1975-1985), a D1 lymphadenectomy was performed in all patients. In the second group (1986-1995) a D1.5 lymphadenectomy without systematic splenectomy and pancreatectomy was applied to 49 patients. RESULTS: In the second group, the proportion of curative resection was higher (85% versus 75%) along with a higher rate of total gastrectomy (42% versus 17%). The postoperative mortality rate was 2% in the first group and 1% in the second group. The morbidity rate was 33% in the first group and 15% in the second group with a rate of anastomotic leak of 11% and 2% respectively. Among the second group, the morbidity rate was 20% after D1,5 lymphadenectomy versus 10% after D1 lymphadenectomy. The overall 5-year survival rate was 29% in the first group versus 38% in the second group. In this latter group, the overall 5-year survival was 32% after D1 lymphadenectomy and 46% after D1,5 (p = 0.038). CONCLUSION: Radical lymphadenectomy without associated splenic or pancreatic resection in good general status patients may provide a better staging of resected gastric cancer without increase of the postoperative mortality. However, the influence of radical lymphadenectomy on long-term survival remains to be proven.     

Results of an aggressive surgical approach to gastric carcinoma during a twenty-three-year period

The early work of Dr. William Longmire with total gastrectomy for gastric carcinoma prompted us to initiate an aggressive surgical approach to gastric carcinoma in 1960: in curative resections radical total gastrectomy with hepaticoceliac-left gastric arterial node dissection was to be performed for tumors involving the entire stomach or upper two thirds and radical 80% to 90% subtotal gastrectomy with similar node dissection for tumors located in the antrum. During a 23-year period 213 patients with confirmed gastric carcinoma were studied. Celiotomy was performed in 192: advanced gastric cancer was found in 185 and seven had early gastric cancer. In only 80 patients could resections for "cure" be done. In 31 patients who underwent total or extended total gastrectomy the operative mortality rate was 9.6%, and life table survival curves show a better survival rate than in 49 patients treated by subtotal gastrectomy, with an operative mortality rate of 16.3%. The study shows the urgent need for diagnosis of early gastric cancer by gastroscopic screening of adults at risk and the meager salvage by radical resection in advanced disease.     

同时发生的食管胃重复癌的外科治疗

目的探讨同时发生的食管、胃重复癌的外科治疗方法及效果.方法1985年1月至2005年1月收治同时发生的食管、胃重复癌12例,均为男性,平均年龄56.8岁.全组均行手术治疗,成功完成同期食管次全切除并全胃切除,结肠代食管并空肠“P”袢代胃重建消化道10例,食管内翻拔脱并全胃切除,结肠代食管并空肠“P”袢代胃重建消化道1例,手术探查1例.结果全组无围术期死亡.术后颈部吻合口瘘2例,不全肠梗阻1例,均经保守治疗后痊愈;术后腹部切口裂开1例,二期缝合治愈.9例获得随访,1、3、5年生存率分别100%、44.4%、22.2%.结论同期食管次全切除并全胃切除,结肠代食管并空肠“P”袢代胃重建消化道是根治同时发生的食管、胃重复癌安全有效的外科治疗方法.     

Is There a Role for Palliative Gastrectomy in Patients with Stage IV Gastric Cancer?

Patients with metastatic gastric cancer are currently not considered operative candidates and are most often offered systemic therapy. Palliative resection of the primary tumor has been considered irrelevant to the outcome and has been recommended only for palliation of symptoms. We have examined the role of palliative gastrectomy and its impact on survival in patients with stage IV gastric cancer at initial diagnosis between 1990 and 2000. A total of 105 patients with stage IV disease were identified during this period; 81 of them (77.1%) had no resection, and 24 (22.9%) underwent palliative gastric resection. Mean survival in those without resection who received chemotherapy (with or without radiation) treatment was 5.9 months (95% confidence interval 4.2–7.6). For those with resection and adjuvant therapy, mean survival time was 16.3 months (95% confidence interval 4.3–28.8 months). Kaplan-Meier survival analysis showed significantly better survival in those with resection and adjuvant therapy (log-rank test, P = 0.01). Mortality and morbidity rates associated with palliative resection were 8.7% and 33.3%, respectively, which did not differ statistically from the 3.7% and 25.3% in patients who underwent curative gastrectomy during same period of time. However, the length of hospitalization (22 versus 16 days) was significantly higher compared with those without stage IV disease. These data suggest that palliative resection combined with adjuvant therapy may improve survival in a selected group of patients with stage IV gastric cancer. Palliative gastrectomy plus systemic therapy should be compared with systemic therapy alone in a randomized trial.     

Extended local resection for advanced gastric cancer: increased survival versus increased morbidity

OBJECTIVE: To characterize factors predictive of improved survival following gastrectomy with additional organ resection for the treatment of gastric cancer. SUMMARY BACKGROUND DATA: Recent large series have reported significant survival disadvantages to patients who have undergone gastrectomy with splenectomy or pancreaticosplenectomy, and yet gastrectomy with additional organ resection is needed to accomplish an R0 resection in some cases. Gastrectomy with splenectomy and other organ resections has been associated with advanced T-stage, positive resection margins, and higher postoperative morbidity and mortality rather than an absolute predictor of survival. METHODS: The authors reviewed the Department of Surgery prospective gastric database at Memorial Sloan-Kettering Cancer Center from July 1985 to July 2000. During this period, of the 2,112 patients with primary gastric cancer, 1,133 underwent an R0 resection. The R0 resection group included 865 patients who underwent gastrectomy alone and 268 patients who underwent gastrectomy with another organ resection. Clinicopathologic, operative, complication, and survival data were compared between these two groups. Chi-square analysis and the Kaplan-Meier method were used to compare and estimate median survival. RESULTS: The most common organs resected were the spleen and pancreas, with an even distribution of other organs. Pathologic factors revealed that the gastrectomy with organ resection group had significantly larger lesions, greater T-stage, and a higher incidence of advanced nodal disease than the group who did not undergo additional organ resection. The incidence of pathologically confirmed T4 cancers in the additional organ resection group was only 14%. The overall 5-year survival rate for patients with T3/T4 disease was 27% with additional organ resection. The overall 5-year survival rate for the gastrectomy with organ resection group (32%, median 32 months) was significantly less than the group that did not undergo additional resection (50%, median 63 months) on univariate analysis. However, additional organ resection was not a predictor of survival on multivariate analysis. Multivariate analysis identified advanced T-stage (T3 or greater) and nodal stage (N1 or greater) as adverse predictors of survival in this group. CONCLUSIONS: Long-term survival following gastrectomy with additional organ resection is possible. Depth of invasion and the extent of lymph node metastasis are the most important predictors of survival following gastrectomy with additional organ resection, and a R0 resection has been achieved. Judicious use of additional organ resection for the treatment of advanced gastric cancer must be emphasized, given the increased overall morbidity and infrequent finding of actual T4 disease. Additional organ resection can be performed with minimal morbidity and can improve the chance of overall survival in patients with advanced T-stage disease.     

胃手术后患者中、上段食管癌的外科治疗

目的探讨胃手术后再患食管中、上段癌的外科治疗方法。方法回顾分析1980—2004年收治的86例胃手术后食管癌患者的临床资料。食管中段癌50例,上段癌31例,颈段5例。TNM分期：Ⅰ期16例,Ⅱa期62例,Ⅱb期5例,Ⅲ期3例。既往曾行全胃或胃部分切除术,术后至诊断为食管癌的时间为2～22年。手术术式：病变食管切除以残胃上提代食管2例,倒置胃管代食管3例,短段带血管蒂结肠问置代食管5例,长段血管蒂结肠代食管74例,空肠造口减状术2例。结果术后30d内出现并发症10例(12％),经处理治愈。76例(88％)病变食管切除,恢复正常进食;7例(8％)病变食管旷置,经口进食;2例空肠造口给肠内营养;1例死亡。术后随访67例,术后1,3,5年生存率分别为84％(56／67),57％(38／67)和22％(15／67)。结论胃手术后再患食管中、上段癌患者的治疗仍首选手术切除病变食管,大部分的病例可采用结肠代食管。     

胃底贲门癌根治性近端胃切除术与全胃切除的临床对照研究及术后随访

目的对比研究全胃切除术和近端胃大部切除术治疗胃底贲门癌的临床疗效。方法回顾性分析64例贲门癌病人的临床资料,其中31例行全胃切除术(total gastrectomy,TG),33例行近端胃大部切除术(proximal gastrectomy,PG),比较其围手术期的情况及术后1年、3年生存率。结果 TG组手术时间为(201±36)min,PG组手术时间为(188±50)min,TG手术失血量为(170±18)ml;PG组失血量为(166±29)ml;TG组术后排气时间为(3.6±0.5)d,PG组通气时间为(3.5±0.6)d;围手术期TG组发生并发症6例,PG组发生8例。两组相比,差异均无统计学意义(P0.05)。TG组1年、3年生存率分别为85%、63%;PG组1年、3年生存率分别为82%、53%。两组1年生存率差异无统计学意义(P0.05),3年生存率TG组明显高于PG组(P0.05)。结论全胃切除术在围手术期间疗效和短期生存率与近端胃切除术差别不大,但其远期疗效较好。